首页> 外文期刊>The Journal of dermatological treatment >beta-Glucan-based cream (containing pleuran isolated from pleurotus ostreatus) in supportive treatment of mild-to-moderate atopic dermatitis
【24h】

beta-Glucan-based cream (containing pleuran isolated from pleurotus ostreatus) in supportive treatment of mild-to-moderate atopic dermatitis

机译:β-葡聚糖乳膏(含有从胸膜分离的胸膜)支持治疗轻度至中度特应性皮炎

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases with serious impact on quality of life. beta-Glucans are natural substances with potent immunomodulatory and anti-inflammatory activity. Methods: In a multicentre open split-body study, we studied the effect of Imunoglukan P4H (R) cream in a group of 105 patients with AD (39 males, 37). Evaluation of subjective (visual analogue scale, VAS) and objective (EASI score, eczema area and severity index) characteristics of AD was carried out. Results: In total, 80 patients (76.2) completed the study. Topical beta-glucan application resulted in the significant improvement of both objective and subjective symptoms of AD. On the application side, significant decline in the number of days with AD exacerbation and its severity was observed. Moreover, the subjects experienced decline of pruritus on the beta-glucan half of the body (VAS score: 1.68 vs. 1.95, p<0.001). During the study, the continual and significant decline of EASI scores on the site of beta-glucan application was observed (V4: 1.57 vs. 1.85, p<0.001). The preparation was in general well tolerated. Conclusions: This is the first study evaluating and confirming the potential use of beta-glucan-based cream as a supportive complementary therapy of atopic dermatitis.
机译:背景:特应性皮炎(AD)是最常见的慢性炎症性皮肤病之一,对生活质量有严重影响。β-葡聚糖是具有有效免疫调节和抗炎活性的天然物质。方法:在一项多中心开放式分体研究中,我们研究了 Imunoglukan P4H (R) 乳膏在一组 105 名 AD 患者(39 名男性,37%)中的效果。评估AD的主观(视觉模拟量表,VAS)和客观(EASI评分,湿疹面积和严重程度指数)特征。结果:总共有 80 名患者 (76.2%) 完成了研究。局部应用β-葡聚糖可显著改善AD的客观和主观症状。在应用方面,观察到AD恶化的天数及其严重程度显着下降。此外,受试者在β-葡聚糖半身的瘙痒中出现下降(VAS评分:1.68 vs. 1.95,p<0.001)。在研究期间,观察到β-葡聚糖应用部位的EASI评分持续显着下降(V4:1.57 vs. 1.85,p<0.001)。该制剂通常耐受性良好。结论:这是第一项评估和确认β-葡聚糖乳膏作为特应性皮炎支持性补充疗法的潜在用途的研究。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号